Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Safety and immunogenicity of SARS-CoV-2 vaccine MVC-COV1901 in adolescents in Taiwan: A double-blind, randomized, placebo-controlled phase 2 trial

Luke Tzu-Chi Liu, Cheng-Hsun Chiu, Nan-Chang Chiu, Boon-Fatt Tan, Chien-Yu Lin, Hao-Yuan Cheng, Meei-Yun Lin, View ORCID ProfileChia-En Lien, Charles Chen, Li-Min Huang
doi: https://doi.org/10.1101/2022.03.14.22272325
Luke Tzu-Chi Liu
1Medigen Vaccine Biologics Corporation, Taipei, Taiwan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Cheng-Hsun Chiu
2Department of Pediatrics, Chang Gung Children’s Hospital, Chang Gung University College of Medicine, Taoyuan City, Taiwan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nan-Chang Chiu
3Department of Pediatrics, MacKay Children’s Hospital, Taipei City, Taiwan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Boon-Fatt Tan
4Department of Pediatrics, National Taiwan University Hospital Hsinchu Branch, Hsinchu County, Taiwan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Chien-Yu Lin
5Department of Pediatrics, Hsinchu MacKay Memorial Hospital, Hsinchu City, Taiwan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hao-Yuan Cheng
1Medigen Vaccine Biologics Corporation, Taipei, Taiwan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Meei-Yun Lin
1Medigen Vaccine Biologics Corporation, Taipei, Taiwan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Chia-En Lien
1Medigen Vaccine Biologics Corporation, Taipei, Taiwan
6Institute of Public Health, National Yang-Ming Chiao Tung University, Taipei City, Taiwan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Chia-En Lien
Charles Chen
1Medigen Vaccine Biologics Corporation, Taipei, Taiwan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: lmhuang@ha.mc.ntu.edu.tw charles@medigenvac.com
Li-Min Huang
7Department of Pediatrics, National Taiwan University Hospital and College of Medicine, National Taiwan University, Taipei, Taiwan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: lmhuang@ha.mc.ntu.edu.tw charles@medigenvac.com
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

Background MVC-COV1901 is a subunit SARS-CoV-2 vaccine based on the prefusion spike protein S-2P and adjuvanted with CpG 1018 and aluminum hydroxide. Although MVC-COV1901 has been licensed for emergency use for adults in Taiwan, the safety and immunogenicity of MVC-COV1901 in adolescents remained unknown. As young people play an important role in SARS-CoV-2 transmission and epidemiology, a vaccine approved for adolescents and eventually, children, will be important in mitigating the COVID-19 pandemic.

Methods This study is a prospective, double-blind, multi-center phase 2 trial evaluating the safety, tolerability and immunogenicity of two doses of the SARS-CoV-2 vaccine MVC-COV1901 in adolescents. Healthy adolescents from age of 12 to 17 years were recruited and randomly assigned (6:1) to receive two intramuscular doses of either MVC-COV1901 or placebo at 28 days apart. The primary outcomes were safety and immunogenicity from the day of first vaccination (Day 1) to 28 days after the second vaccination (Day 57), and immunogenicity of MVC COV1901 in adolescents as compared to young adult vaccinees in terms of neutralizing antibody titers and seroconversion rate. The secondary outcomes were safety and immunogenicity of MVC-COV1901 as compared to placebo in adolescents in terms of immunoglobulin titers and neutralizing antibody titers over the study period.

Results Between July 21, 2021 and December 22, 2021, a total of 399 adolescent participants were included for safety evaluation after enrollment to receive at least one dose of either MVC-COV1901 (N=341) or placebo (N=58). Of these, 334 and 46 participants went on to receive two doses of either MVC-COV1901 or placebo, respectively, and were included in the per protocol set (PPS) for immunogenicity analysis. Adverse events were mostly mild and were similar in MVC-COV1901 and placebo groups. The most commonly reported adverse events were pain/tenderness and malaise/fatigue. All immunogenicity endpoints in the adolescent group were non-inferior to the endpoints seen in the young adult and placebo groups.

Conclusions The safety and immunogenicity data presented here showed that MVC-COV1901 has similar safety profile and non-inferior immunogenicity in adolescents compared to young adults.

ClinicalTrials.gov registration NCT04951388.

Competing Interest Statement

L. T.-C. L., C. E. L., M.-Y. L., H.-Y. C. and C. C. are employees of Medigen Vaccine Biologics Corporation and have received grants from the Taiwan Centers of Disease Control, Ministry of Health and Welfare. L.-M. H. declared no conflict of interest. All authors have reviewed and approved of the final version of the manuscript.

Clinical Trial

NCT04951388

Funding Statement

This study was funded by Medigen Vaccine Biologics Corporation (MVC, the study sponsor) and Taiwan Centers for Disease Control (CDC), Ministry of Health and Welfare. MVC had a role in study design, data analysis, and data interpretation, but had no role in data collection, or writing of the clinical report. Taiwan CDC of the Ministry of Health and Welfare had no role in study design, data collection, data analysis, data interpretation, or writing of the report.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The trial protocol and informed consent form were approved by Taiwan Food and Drug Administration (TFDA) and the ethics committees at the conducting sites: Mackay Memorial Hospital Hsinchu (Hsinchu City), Chang-Gung Memorial Hospital Linkou (New Taipei City), Mackay Memorial Hospital (Taipei City), National Taiwan University Hospital Hsinchu (Hsinchu City), and National Taiwan University Hospital (Taipei City).

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

All data produced in the present work are contained in the manuscript

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license.
Back to top
PreviousNext
Posted March 15, 2022.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Safety and immunogenicity of SARS-CoV-2 vaccine MVC-COV1901 in adolescents in Taiwan: A double-blind, randomized, placebo-controlled phase 2 trial
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Safety and immunogenicity of SARS-CoV-2 vaccine MVC-COV1901 in adolescents in Taiwan: A double-blind, randomized, placebo-controlled phase 2 trial
Luke Tzu-Chi Liu, Cheng-Hsun Chiu, Nan-Chang Chiu, Boon-Fatt Tan, Chien-Yu Lin, Hao-Yuan Cheng, Meei-Yun Lin, Chia-En Lien, Charles Chen, Li-Min Huang
medRxiv 2022.03.14.22272325; doi: https://doi.org/10.1101/2022.03.14.22272325
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Safety and immunogenicity of SARS-CoV-2 vaccine MVC-COV1901 in adolescents in Taiwan: A double-blind, randomized, placebo-controlled phase 2 trial
Luke Tzu-Chi Liu, Cheng-Hsun Chiu, Nan-Chang Chiu, Boon-Fatt Tan, Chien-Yu Lin, Hao-Yuan Cheng, Meei-Yun Lin, Chia-En Lien, Charles Chen, Li-Min Huang
medRxiv 2022.03.14.22272325; doi: https://doi.org/10.1101/2022.03.14.22272325

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (230)
  • Allergy and Immunology (507)
  • Anesthesia (111)
  • Cardiovascular Medicine (1264)
  • Dentistry and Oral Medicine (207)
  • Dermatology (148)
  • Emergency Medicine (283)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (538)
  • Epidemiology (10056)
  • Forensic Medicine (5)
  • Gastroenterology (502)
  • Genetic and Genomic Medicine (2486)
  • Geriatric Medicine (240)
  • Health Economics (482)
  • Health Informatics (1653)
  • Health Policy (757)
  • Health Systems and Quality Improvement (638)
  • Hematology (250)
  • HIV/AIDS (538)
  • Infectious Diseases (except HIV/AIDS) (11896)
  • Intensive Care and Critical Care Medicine (627)
  • Medical Education (255)
  • Medical Ethics (75)
  • Nephrology (269)
  • Neurology (2304)
  • Nursing (140)
  • Nutrition (354)
  • Obstetrics and Gynecology (458)
  • Occupational and Environmental Health (537)
  • Oncology (1259)
  • Ophthalmology (377)
  • Orthopedics (134)
  • Otolaryngology (226)
  • Pain Medicine (158)
  • Palliative Medicine (50)
  • Pathology (326)
  • Pediatrics (737)
  • Pharmacology and Therapeutics (315)
  • Primary Care Research (282)
  • Psychiatry and Clinical Psychology (2295)
  • Public and Global Health (4850)
  • Radiology and Imaging (846)
  • Rehabilitation Medicine and Physical Therapy (493)
  • Respiratory Medicine (657)
  • Rheumatology (289)
  • Sexual and Reproductive Health (241)
  • Sports Medicine (228)
  • Surgery (273)
  • Toxicology (44)
  • Transplantation (131)
  • Urology (100)